This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Gastric inhibitory polypeptide
- DrugBank Accession Number
- DB15217
- Background
Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Gastric inhibitory polypeptide. Acebutolol The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acebutolol. Acetazolamide The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acetazolamide. Acetohexamide The risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Gastric inhibitory polypeptide. Acetyl sulfisoxazole The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acetyl sulfisoxazole. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1O4H75S7H2
- CAS number
- 100040-31-1
References
- General References
- Not Available
- External Links
- Wikipedia
- Gastric_inhibitory_polypeptide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Diabetes 1 1 Completed Treatment Type 2 Diabetes Mellitus 1 1, 2 Completed Basic Science Diabetes Mellitus 1 Not Available Completed Not Available Cystic Fibrosis (CF) 1 Not Available Completed Not Available Type 2 Diabetes Mellitus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at May 20, 2019 15:01 / Updated at June 12, 2020 16:53